Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Scotiabank
Scotiabank began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set a “sector outperform” rating and a $32.00 price target on the biotechnology company’s stock. Scotiabank’s price objective would suggest a potential upside of 151.37% from the company’s previous close. A […]
Scotiabank began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set a “sector outperform” rating and a $32.00 price target on the biotechnology company’s stock. Scotiabank’s price objective would suggest a potential upside of 151.37% from the company’s previous close. A […]
